Good point. Still, do we really think the additional resources for generics approvals will *only* go to new ANDA's?
Let's say genericX files today, and tomorrow the legislation is approved. Day after tomorrow genericY files and pays the extra fee. Is genericX really going to still have a 31 month timeline, while genericY gets approved in 10 months?
Maybe. But I would guess (hope) that some of the new resources would also go to clearing the existing backlog (M-Copaxone included) along with speeding new approvals.